Allegan

perrigologo

Perrigo-Elan Deal Takes A Step Forward With Irish High Court Approval

Allegan-based Perrigo Co. (NYSE:PRGO) and Ireland’s Elan Corp. plc (NYSE:ELN) Friday announced that the Irish High Court has approved Perrigo’s pending acquisition of Elan.

WWJ Newsradio 950–12/15/2013

perrigo

Perrigo Updates Note Offer

Perrigo Co. (NYSE: PRGO) announced that, in connection with its offer to purchase for cash its 2.950% Notes due 2023, it has received the requisite consents to amend the indenture governing the notes.

WWJ Newsradio 950–11/21/2013

perrigologo

Perrigo Confirms Filing For Generic Version Of Acanya

The Allegan generic drugmaker and store brand health products producer Perrigo Co. (NYSE: PRGO) Wednesday announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% and has notified Dow Pharmasciences, the owner of the New Drug Application, of its filing.

WWJ Newsradio 950–11/20/2013

perrigo

Perrigo Shareholders Approve Elan Acquisiton

The generic prescription drug and store-brand health products maker Perrigo Co. (NYSE: PRGO) announced that its shareholders approved proposals related to its acuqisition of Ireland’s Elan Corp. plc at a special meeting Monday.

WWJ Newsradio 950–11/18/2013

perrigologo

Perrigo Company Announces Quarterly Dividend

Perrigo Co. (NYSE: PRGO) announced that its board declared a quarterly dividend of 9 cents per share, payable Dec. 17 to shareholders of record on Nov. 29.

WWJ Newsradio 950–11/06/2013

perrigologo

Perrigo Co. Selling $2.3 Billion In Debt To Finance Elan Purchase

The Allegan generic pharmaceutical and store-brand health products maker Perrigo Co. Ltd., which moved its corporate registration to Ireland earlier this year, said it would offer debt totaling $2.3 billion with maturities in 2016, 2018, 2023 and 2043.

WWJ Newsradio 950–11/05/2013

perrigologo

Perrigo Profits, Sales Rise

The generic pharmaceutical and store-brand helath products maker Perrigo Co. (NYSE: PRGO) Thursday reported net income of $111.4 million or $1.18 a share in the first fiscal quarter ended Sept. 28, up from $105.6 million or $1.12 a share in the first fiscal quarter a year earlier. Revenue was $933.4 million, up from $769.8 million a year earlier.

WWJ Newsradio 950–10/31/2013

perrigologo

Perrigo Sets Date Of Shareholder Meeting To Approve Elan Acquisition

Perrigo Co. (NYSE: PRGO) announced that it has scheduled a shareholder meeting for Monday, Nov. 18 in connection with Perrigo’s proposed previously announced acquisition of Elan Corp. (NYSE: ELN).

WWJ Newsradio 950–10/10/2013

perrigologo

Perrigo Announces FDA Final Approval For Generic Version Of Nitrolingual Spray

Perrigo Co. (NYSE: PRGO) announced that it has received final approval for its abbreviated new drug application for nitroglycerin lingual spray, 400 mcg/spray, the generic equivalent to Nitrolingual Pumpspray.

WWJ Newsradio 950–09/23/2013

perrigologo

Perrigo Company Gets FDA Approval For Generic Zyrtec For Kids, Presents At Conferences

Perrigo Co. (NYSE: PRGO) announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for cetirizine hydrochloride oral solution USP, 1 mg/mL, bubble gum flavored, the store brand equivalent to Children’s Zyrtec Allergy Syrup, 1 mg/mL, bubble gum flavored.

WWJ Newsradio 950–09/10/2013

more

Follow

Get every new post delivered to your Inbox.

Join 1,974 other followers